Report results from period one of batoclimab trial in chronic inflammatory demyelinating polyneuropathy
Delivered by the deadline
AI-assessed · human review in progress Found and assessed by AI from the cited sources. Shown with its evidence; it is not counted in any Kept Score until confirmed.
- Announced
- 6 Feb 2025
- Due
- 31 Mar 2025
- Delivered
- 19 Mar 2025
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Results from period one of the trial evaluating batoclimab in CIDP continue to be expected by March 31, 2025.”
What we found
Evidence strength A What the grades mean
Immunovant reported initial Period 1 CIDP batoclimab trial results on March 19, 2025, ahead of the March 31, 2025 deadline.
-
A Immunovant, Inc. - Form 8-K Exhibit 99.1 (March 19, 2025) Official press release announcing Period 1 CIDP batoclimab results
-
B Immunovant Announces Positive Results for Batoclimab MG and CIDP Studies News release confirming Period 1 CIDP results reported March 19, 2025
-
B 8-K - 03/19/2025 SEC filing confirming press release date and content on CIDP results
Checked 12 Sep 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical readout
- Indicative materiality
- Medium rules
- Action
- Report
- Language
- Expected (“expects”, “plans”)
How this entry was checked
- Commitment recordedRecorded from the company's filing.
- First checkAn AI model read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Gemini (Google), re-read the evidence without being told the outcome and reached the same answer.
Not yet confirmed. Shown on the record, but it will not count in any score until it is confirmed. How verification works
Are you Immunovant, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2025-IMVT-000329 · Corrections policy